150 Dan Road
About Organogenesis Inc
69 articles with Organogenesis Inc
Class A Common Stock to Resume Trading on Nasdaq
Organogenesis Holdings Inc. Announces Completion Of Merger Of Avista Healthcare Public Acquisition Corp. And Organogenesis Inc.
Organogenesis Holdings Inc. today announced the completion of its previously announced business combination between Organogenesis Inc. and Avista Healthcare Public Acquisition Corp. ("AHPAC").
Organogenesis Celebrates Launch of Advancing Healing Education Resource Center and Highlights Latest Wound Care Research at SAWC Fall 2018
Organogenesis Inc. will celebrate the launch of the Advancing Healing Education Resource Center, a continuing medical education microsite covering the latest clinical and practical developments in wound healing, as well as showcase the company's latest product research during the Symposium on Advanced Wound Care (SAWC) Fall 2018 meeting held this week in Las Vegas.
Organogenesis Inc. Announces 2018 Sponsorship of American Podiatric Medical Association Education Programs, Annual Scientific Meeting
Organogenesis Inc. announced its 2018 sponsorship of the American Podiatric Medical Association (APMA)
Thomas Pearl Welcomed to Organogenesis Leadership Team
Organogenesis Comparative Effectiveness Research Demonstrating Faster VLU Time to Healing with Apligraf® Showcased at ISPOR
New comparative effectiveness research from Organogenesis Inc. demonstrating faster time to healing and greater healing rates with Apligraf® for the treatment of venous leg ulcers (VLUs) was showcased last week at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2018 meeting.
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
Gary S. Gillheeney, Sr., President and CEO of Organogenesis Inc., has been appointed to the Massachusetts Biotechnology Council (MassBio) Board of Directors
Organogenesis Inc., a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets, today announced its PuraPly® Antimicrobial (AM) wound management product is now available in a new, easy-to-use 1.6 cm disc size.
Advanced Medical Solutions Group plcand Organogenesis today announced the two companies have entered into an out-licensing agreement on a U.S. patent for a collagen-based wound dressing containing Polyhexamethylene Biguanide.
Organogenesis Release: Apligraf Is First Wound Healing Therapy To Demonstrate Significant Change In Chronic Wound's Genomic Profile
Organogenesis Release: PuraPly and PuraPly Antimicrobial (AM) Receive Permanent Q-Code, Expanding Medicare Coverage After January 1 To Include Treatment In Private Physician Office Setting
Organogenesis Release: Nation's Leading Developer Of Advanced Wound Care Technologies Urges FDA To Finalize Regulatory Guidance To Ensure Safety And Efficacy Of Section 361 HCT/Ps
Organogenesis Release: Advanced Wound Care Products Puraply And Puraply Antimicrobial Now Available For Medicare Reimbursement In 10 States